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Summary 
 
Background and Purpose 
Nitric oxide (NO) derived from eNOS is mostly responsible for the maintenance of 
vascular homeostasis where decrease in its bioavailability is characteristic of ROS-
induced endothelial dysfunction (ED). Since 5,5-Dimethyl-1-pyrroline-N-oxide (DMPO), 
a commonly used spin trap, has been shown to control intracellular nitroso-redox balance 
by scavenging ROS and donating NO it was employed as cardio-protective agent against 
ED but the mechanism of its protection is still not clear. This study elucidates the 
mechanism of protection imparted by DMPO against SIN-1-induced oxidative injury to 
bovine aortic endothelial cells (BAEC).  
Experimental Approach 
BAEC were treated with SIN-1 as ONOO
−
 donor and post-incubated with DMPO. MTT 
assay was employed to assess cytotoxicity by SIN-1 and cytoprotection by DMPO. 
Levels of ROS and NO generation from HEK293 cells transfected with wild type and 
mutant eNOS cDNAs, BH4 bioavailability, eNOS activity, eNOS and Akt kinase 
phosphorylation were determined.  
Key Results 
Post-treatment of cells with DMPO attenuated SIN-1-mediated cytotoxicity and ROS 
generation, restoration of NO levels via increased in eNOS activity and phospho-eNOS 
levels. Treatment with DMPO alone significantly increased NO levels and induced 
phosphorylation of eNOS S1179 via Akt kinase. Transfection studies with wild type and 
mutant human eNOS confirmed a dual role of eNOS as O2
•− 
with SIN-1 treatment and 
NO producer in the presence of DMPO. 
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Conclusion and Implications 
This study demonstrates that post-treatment with DMPO of oxidatively challenged cells 
can impart reversal of eNOS dysfunction and can have pharmacological implications in 
the treatment of cardiovascular diseases. 
Keywords 
eNOS; DMPO; spin trapping; endothelial dysfunction; peroxynitrite; oxidative stress; 
reactive oxygen species; nitric oxide; cardiovascular diseases; endothelial cells 
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Introduction 
 Oxidative stress resulting from the overproduction of reactive oxygen species 
(ROS), leads to endothelial dysfunction which is implicated in pathophysiology of 
several cardiovascular disorders (CVD) such as atherosclerosis, hypercholesterolemia, 
hypertension, Type 2 diabetes, and heart failure (Cai et al., 2000; Heitzer et al., 2001; 
Vita, 2011). Excessive ROS generation within the vasculature may lead to the oxidation 
of low-density lipoproteins, decreased bio-availability of endothelium-derived nitric 
oxide (NO) (O'Donnell et al., 2001) and formation of peroxynitrite (ONOO
─
), a highly 
reactive molecule (Beckman et al., 1996). All these events are attributed to the 
impairment of the vascular endothelium function. 
Endothelium –derived nitric oxide (NO) is an important signaling molecule which 
regulates the vessel homeostasis by inducing vascular smooth muscle relaxation, and 
inhibiting vascular smooth muscle hypertrophy, regulating platelet aggregation, and 
leukocyte adhesion (Gross et al., 1995). In the endothelium, NO is produced by a family 
of enzymes termed nitric oxide synthases (NOSs) that catalyze the conversion of L-
arginine to L-citrulline and NO. The reactive oxygen and nitrogen species generated 
during oxidative stress are known to induce eNOS dysfunction that leads to the 
uncoupling of the enzyme and results in the production of NOS-derived O2
•−
 instead of 
NO (Wei et al., 2003). The resulting imbalance between NO and O2
•−
 can contribute to 
the onset of a variety of cardiovascular diseases.  
NOS activity is regulated by a complex cascade of phosphorylation/de-
phosphorylation at particular regulatory residues in the enzyme. Phosphorylation of 
eNOS S635 and S1179 leads to the activation of eNOS function while phosphorylation at 
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threonine 497 downregulates it (Harris et al., 2001; Michell et al., 2001). Activation by 
eNOS S1179 phosphorylation results from the enhanced electron flux through the 
reductase domain and inhibition of calmodulin-dissociation from the enzyme in a 
calcium-independent fashion (Fulton et al., 1999; McCabe et al., 2000) andis mediated 
by several upstream kinases, among which PI3/Akt has been reported to play a crucial 
role in the regulation of enzyme activity (Fulton et al., 1999). 
Most of the NO donor drugs are limited only by their NO delivering property and 
usually exhibit uncontrolled delivery of NO due to their instability in blood plasma 
(Wang et al., 2005). Nitrones can both scavenge reactive species (Villamena et al., 2005; 
Villamena et al., 2004) and also exhibit controlled release of NO as a consequence 
(Locigno et al., 2005; Nash et al., 2012), and is therefore, more desirable and unique 
among current drugs. To date, there are two major types of nitrones: the cyclic nitrones 
which include 5,5-dimethyl-1-pyrroline-N-oxide (DMPO), 5-carbamoyl-5-methyl-1-
pyrroline-N-oxide (AMPO), 5-ethoxycarbonyl-5-methyl-1-pyrroline-N-oxide (EMPO), 5-
(diethoxyphosphoryl)-5-methyl-1-pyrroline-N-oxide (DEPMPO), and the linear nitrones 
(PBN and NXY-059) α-phenyl-N-tert-butylnitrone (PBN), (disodium-[(tert-butylimino) 
methyl] benzene-1,3-disulfonate N-oxide (NXY-059) which have been used to detect free  
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radicals. Nitrones though structurally simple molecules, yet they possess rich chemistries, 
and biological properties that make them important pharmacological agents (Das et al., 
2012; Traynham et al., 2012; Villamena et al., 2012; Zamora et al., 2013; Zuo et al., 
2009). Nitrone spin traps such as DMPO, PBN and its derivative, NXY-059 have shown 
pharmacological activity against ischemia and reperfusion (I/R) injury in the heart and 
brain (Floyd, 2009; Zuo et al., 2009), neurodegeneration (Floyd et al.) and cancer (Floyd, 
2009; Floyd et al., 2008). NXY-059 was the first neuroprotective agent that reached a 
clinical trial phase in the USA (Floyd et al., 2008). Application of DMPO as a cardio-
protective agent was previously reported (Tosaki et al., 1990) but its modes of action 
were unclear. DMPO also confered protection against cardiac IR injury in Langendorff 
rat heart preparations by salvaging the METC complexes and decreased ROS production 
(Zuo et al., 2009). Other experimental evidences suggest involvement of other 
mechanisms for cardioprotection by DMPO other than its direct spin trapping properties 
such as induction of phase II enzymes via Nrf-2 nuclear translocation; and suppression of 
mitochondria-dependent pro-apoptotic signaling in endothelial cells (Das et al., 2012). 
Increase in mycoyte contraction via regulation of nitroso-redox levels and increase in 
sarcoplasmic reticulum Ca
2+
 handling have also been proposed (Traynham et al., 2012). 
Although several works already described the reversal of eNOS uncoupling via 
supplementation with tetrahydrobiopterin (Forstermann, 2006), in the present study, we 
explored the mechanism of reversal of eNOS dysfunction by post-treatment of 
endothelial cells with DMPO after treating the cells with the peroxynitrite donor, SIN-1, 
offering another mechanistic insights into the cardioprotective property of nitrones. 
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Methods 
Cell culture and maintenance 
 BAEC were cultured using a T75 cm
2 
flask in DMEM medium with 1g/L D-
glucose and 4 mM L-glutamine, and supplemented with 10% fetal bovine serum, 50 
µg/mL pencillin, 50 µg/mL streptomycin, 2.5 mg/L endothelial cell growth supplement, 
and 1% MEM-non essential amino acids at 37°C in a humidified atmosphere of 5% CO2 
and 20% O2. HEK293 (human embryonic kidney) were cultured under same conditions 
in DMEM media without endothelial cell growth supplement, and MEM-non essential 
amino acids. The medium was changed every 2-3 days and cells were sub-cultured once 
they reached 90-95% confluence or 80% for HEK293 cells.  
 
SIN-1 and DMPO treatment of cells 
 BAEC or HEK293 were seeded at a density of 10
4
 cells/mL in each well using a 
24-well plate and grown to 70% confluency. Cells were treated with 500 µM SIN-1 for 2 
h, and then post-incubated in plain medium without SIN-1 for additional 24 h, in the 
absence or presence of DMPO. For the cytoprotection studies, cells were treated with 500 
µM SIN-1 for 2 h and subsequently post-incubated with DMPO for 24 h. Cell viability 
was assessed by MTT assay following the protocol described previously (Das et al., 
2010).  Cell viability was calculated as the percentage of inhibition by the following 
formula (equation 1) :   
                                      % inhibition = [1-At/As] x 100%                                          (1) 
where At and As are absorbance of the sample and solvent alone, respectively. Results 
were presented as mean ± SEM, where n = 6. 
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ROS detection by confocal microscopy  
 Cells with density of 10
4
 cells/mL were seeded on sterile glass cover slips 6-well 
plate. Treated cells were fixed with 10% para-formaldehyde at room temperature for 10 
min, washed with PBS three times and subsequently incubated with 25 μM of the 
fluorogenic probe DCFH-DA or 10 μM DHE for 30 min at 37°C, followed by nuclei 
staining with DAPI (1 µM) for 30 min. Images were then captured by Olympus 
FluoView-1000 confocal microscope using an excitation/emission filter of 543/602 nm 
for DHE, 488/535 nm for DCFH-DA and 405/422 nm for DAPI. Fluorescence intensities 
of 100 cells from different fields were calculated and results were presented as mean ± 
SEM of three independent experiments (n = 3).  
 
ROS and NO detection by EPR spin trapping 
 Cells (10
4
 cells/mL ) were grown to 70 % confluency in 6-well plates. After SIN-
1 treatment, cells were incubated with 150 µl of EMPO (25 mM) and 150 µl of Me-β-CD 
(50 mM) and 10 µl of 10 μM CaI for 15 min (Šnyrychová, 2010). The supernatant (300 
µl) was transferred to a quartz flat cell and spin adduct formation was detected at room 
temperature using Bruker EMX X-Band EPR spectrometer. Experiment was repeated in 
the presence or absence of DMPO post-incubation.  Instrument parameters were as 
follows: microwave frequency, 9.8 GHz; center field, 3485 G; modulation amplitude, 
0.2-1.0 G; microwave power, 10 mW; conversion time: 41 ms; time constant: 82 ms, 
sweep time: 42 s; sweep width: 120 G; receiver gain, 1 x 10
5
 and using incremental 
sweep. Spectra were simulated using an automatic fitting program (Rockenbauer et al., 
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1996) where the pertinent hfsc’s of HO2
•
, HO
•
 and C-centered  adducts and their 
concentrations from the total area of each spectrum were obtained. Adducts were 
independently prepared using hypoxanthine-xanthine oxidase, Fe
2+
-H2O2 and Fe
2+
-H2O2-
ethanol for HO2
•
, HO
•
 and C-centered  adducts respectively (Table S3). Spectra were 
obtained from three independent experiments (n = 3). Using the same cell cultures in 6-
well plates, generation of NO in cells were detected by EPR spin trapping using 
Fe(MGD)2 as the spin trap following the published protocol (Gopalakrishnan et al., 
2012).  Cells were washed with PBS after treatment, then incubated for 15 minutes with 
PBS with CaCl2 and MgCl2, calcium ionophore A21387 (10 μM), FeSO4 (3.5 mM), and 
ammonium N-methyl-D-glucamine dithiocarbamate complex NH4MGD (20.8 mM) at a 
final volume of 500 μL. The supernatant (300 µl) was transferred to a quartz flat cell and 
spin adduct formation was detected at room temperature with EPR instrument 
parameters: microwave frequency, 9.8 GHz; center field, 3426.5 G; modulation 
amplitude, 6 G; microwave power, 12 mW; conversion time: 10 ms; time constant: 20 
ms, sweep time: 10 s; sweep width: 100 G; receiver gain, 1 x 10
5
 and using incremental 
sweep. The 2-D spectra were integrated and baseline corrected using Bruker WinEPR 
data processing software. Results are as mean ± SEM of three independent experiments 
(n = 3).  
 BAEC in a T75 cm
2 
culture flask were serum-starved overnight then endogenous 
L-[
14
N]-arginine was exchanged for L-[
15
N]-arginine by incubating cells with Tyrode's 
solution supplemented with 84 mg/L L-[
15
N]-arginine for 30 min at 37° C. After 
incubation, cells were washed with PBS, treated with Fe(MGD)2 as above and EPR 
spectra were acquired (Gopalakrishnan et al., 2012).  
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Determination of eNOS activity 
 eNOS activity was determined using the conversion of arginine to citrulline assay 
with [
14
C]arginine as a substrate using the previously published protocol with a slight 
modification (Giraldez et al., 1998). Cultured BAEC (10
4
 cells/ mL) were grown to 70 % 
confluency in T75 cm
2 
culture flask and subjected to SIN-1 treatment and DMPO post-
treatment. After treatment, eNOS activity was measured by L-[
14
C]arginine to L-
[
14
C]citrulline conversion in a total volume of 50 µL buffer containing 50 mM Tris-HCl, 
pH 7.4, 1 µM L-[14C]arginine, 1 mM NADPH, 0.6 mM Ca2+, 2.5µM calmodulin, and 10 
µM BH4. After 10 min incubation at 37°C, the mixture was terminated by adding 400 µL 
of stop buffer (20 mM HEPES, pH 5.5, 2 mM EDTA, 2 mM EGTA). L-[
14
C]citrulline 
was separated by mixing the reaction mixtures with 100 µL of pre-equilibrated Dowex 
AG 50W-X8 (Na
+
 form) cation exchange resin, then passed through spin columns and 
quantitated by liquid scintillation counter. Results were presented as mean ± SEM of 
three independent experiments (n = 3). 
 
Measurement of BH4 by HPLC chromatography 
 The total BH4 was measured using HPLC analysis as described elsewhere 
(Dumitrescu et al., 2007; Hyland, 1985). Cells were grown in T75 cm
2
 flask up to 70% 
confluency. SIN-1 treated cells were washed once with PBS and lysed with lysis buffer 
containing 1 mM ascorbate, 1 mM DTT and 100 μM DTPA, followed by sonication.  The 
mixture was then centrifuged at 12000 x g for 1 min at 4 
o
C. The supernatant containing 
the protein was removed by filtration through a Microcom YM-3 spin column. The 
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filtrates were injected to an ESA HPLC system with a C-18 column (T3 4.6 x 150 mm 5 
micron) and HPLC separation was performed following the published protocol 
(Dumitrescu et al., 2007; Hyland, 1985) using mobile phase comprising of 50 mM 
potassium phosphate, 10 mM phosphate monobase, 12% ACN, 6 mM citric acid, 1 mM 
DTT, 5 mM octyl sulfate, pH 3 and isocratic elution at 1.2 mL/min. Detection parameters 
are: 35mV and 500mV for electrochemical cell; fluorescence: excitation at 348 nm and 
emission at 444 nm; UV at 254 nm. Results were presented as mean ± SEM of three 
independent experiments (n = 3).  
Western blot analysis 
 Western blot analysis was performed to determine the expression levels of p-
eNOS, p-Akt, t-Akt and t-eNOS proteins in untreated, SIN-1 treated, and nitrone-post 
incubated SIN-1 treated BAEC. Prior to treatment, cultured BAEC (10
4
 cells/ mL) were 
grown to 70 % confluency on 60 mm petri-dishes, and 50 µg of protein from each set was 
used for western blotting. In a separate experimental set, the membrane was incubated 
with mouse monoclonal anti-p-eNOS (S1179) antibody (1:1000 dilution), mouse 
monoclonal anti p-Akt (Ser-473) antibody (1:500 dilution), mouse monoclonal anti-t-
eNOS antibody (1:1000 dilution), mouse monoclonal anti-t-Akt antibody (1:500 dilution) 
and mouse monoclonal anti-β-actin antibody (1:1000 dilution) overnight at 4 oC. The 
protein bands were visualized using chemiluminiscence kit available commercially and 
the bands were quantified densitometrically using available software. 
 
Transient transfection of HEK293 cells with wild type and mutant eNOS cDNAs  
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 Human embryonic kidney cells were transfected with 5 µg/µl of eNOS cDNA 
(wild type and mutant where S1179 was changed to alanine) (Lin et al., 2003) using 
Lipofectamine 
TM
 2000 (Invitrogen) as per manufacturer’s instruction. The transfection 
efficiency was analyzed using western blot analysis of eNOS proteins and by measuring 
NO levels. 
 
Statistical analysis 
 Data are presented as the mean of at least three independent experiments along 
with standard error of the mean (SEM). Statistical analysis of data was done by one-way 
analysis of variance (ANOVA), with Student-Newman-Keul test by using Sigma plot 
12.0.  The p value  <0.05 was considered to be statistically significant. 
 
Results 
Dose- and time-dependent cytoprotective effects from post-treatment by DMPO of SIN-
1-challenged BAEC 
 Treatment of cells with varying concentrations of DMPO alone (25- 500 µM) for 
24 h did not result in loss of cell viability (Figure S1). However, cells challenged with 
500 µM SIN-1 at varying time periods resulted in significant cytotoxicity (Figure S2). A 
50% decrease in cell viability was observed after 2 h of  SIN-1 treatment followed by 24 
h of post-incubation in plain media (without SIN-1) (Figure S2). SIN-1 has been 
suggested to induce cell death via two mechanisms, production of peroxynitrite 
(ONOO
─
) through reaction between NO and O2
•− 
to finally form HO
• 
(Ishii et al., 1999), 
and generation of H2O2 (Lomonosova et al., 1998). When SIN-1-challenged cells were 
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post-incubated with DMPO, significant increase in cell viability was observed in both 
dose- and time-dependent fashion (Figures 1A and 1B). Highest cytoprotection was 
observed when SIN-1 treated cells were post-incubated with 100 µM of DMPO for 24 h 
compared to pre-treatment of BAEC with DMPO for 24 hours prior to 2 h SIN-1 
treatment that shows no significant reduction in cell viability (data not shown). Hence, 
from here onwards, cells will be post-treated with 100 µM of DMPO after SIN-1 
challenge.  
 
Attenuation of
 
ROS generation in SIN-1-treated BAEC by DMPO 
 To test if cells generate O2
•− 
after treatment with SIN-1, EPR spin trapping was 
performed using EMPO/Me-β–CD as spin trap on SIN-1-treated BAEC at various times 
(0-24 h) of incubation. EPR results showed increased ROS intensities with increasing 
time of post-incubation along with the formation of a C-centered adduct which could be 
formed as secondary products (Figure S3A and Table S1 for the simulation). The low-
field peak intensity of the EPR spectra increased significantly in SIN-1 treated cells by up 
to 2.9-fold after 24 h of post-incubation (Figure S3B). EPR results were confirmed by 
confocal microscopy using DHE staining of SIN-1-treated cells at different time points. 
Treatment of cells with SIN-1 for 2 h (corresponding to 0 h of post-incubation) resulted 
in a significant increase of DHE-fluorescence specific for O2
•−
 and the signal remained 
persistent for up to 6 h of post-incubation in plain media with fluorescence decreases 
upon further incubation for 12 h and 24 h (Figure S4).  
 Since H2O2 could be also form from SIN-1 treatment via O2
•−
 dismutation 
(Lomonosova et al., 1998), we performed a time-dependent confocal microscopy study 
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on SIN-1-treated BAEC by staining the cells with H2O2-specific fluorescent probe, CM-
DCFDAHE (Figure S5). SIN-1-untreated BAEC showed no detectable DCF-fluorescence 
signal indicating that the cells did not produce H2O2. However, when BAEC were treated 
with SIN-1 for 2 h and post-incubated for an additional 24 h, a time-dependent 
accumulation of DCF-fluorescence signal was detected (Figure S5). 
 When SIN-1-challenged cells were post-treated with 100 µM DMPO, DCF-
fluorescence intensity was found to be significantly decreased (Figures 2A and 2B) 
compared to a 3-fold increase in DCF- fluorescence in SIN-1 treated cells without DMPO 
post-treatment.  Simulation of the EPR spectra also revealed that the concentration of O-
centered adduct was significantly decreased with a concomitant decrease in the 
concentration of C-centered adducts when SIN-1-treated BAEC were post-incubated with 
DMPO for 24 h (Table S2 and Figures 2C-2D.  
 
Restoration of NO bioavailability in SIN-1-treated BAEC by DMPO  
 Since oxidative stress leads to decreased bioavailability of NO (Cai et al., 2000), 
the effect of SIN-1 on NO production in BAEC was investigated. Using EPR and 
Fe(MGD)2 as spin trap to detect NO generation (Figures 3A and 3B), a significant 
decrease in NO production of almost 50% was observed when cells were treated with 
SIN-1 for 2 h and post-incubated in plain media for 24 h. The same observation was 
previously reported for BAEC upon treatment with SIN-1 or ONOO
─  
(Kuzkaya et al., 
2003). However, post-treatment with DMPO for 24 h resulted in the restoration of the 
NO levels by about 35%. Treatment of cells with the NOS inhibitor L-NAME, 
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completely abolished the NO-signal (Figure 3B) indicating an eNOS-derived NO 
production. 
 
Restoration of eNOS activity in SIN-1-treated BAEC by DMPO 
 eNOS activity was assessed using the L-[
14
C] arginine to L-[
14
C] citrulline 
conversion assay. BAEC were treated with SIN-1 for 2 h and post-incubated for another 
24 h that resulted in significant inhibition of eNOS activity by ~30%. However, post-
treatment with DMPO for 24 h led to the complete restoration of eNOS activity (Figure 
3C). This provides definitive evidence that the effects of DMPO on NO production are 
mediated at least in part through increased eNOS-derived NO production and not merely 
a consequence of scavenging SIN-1-derived superoxide.  
 
Increased bioavailability of NO in BAEC treated with DMPO alone 
 Since post-treatment with DMPO resulted in a significant increase in NO 
production and NOS activity in SIN-challenged cells, we investigated if the nitrone alone 
could increase NO generation in BAEC without oxidatively challenging the cells. EPR 
studies revealed that treatment of cells with DMPO resulted in a time-dependent increase 
in cellular NO and a 40% increase in NO production was observed after 24 h of treatment 
(Figure 4).  
 
Determination of NO source: nitrone versus L-Arginine 
 To determine if the source of the generated NO is through nitrone-decomposition 
(Locigno et al., 2005) or eNOS-catalyzed conversion of L-arginine to L-citrulline, an 
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isotope-labeling experiment using L-[
15
N]-arginine was carried out. Due to the difference 
in the nuclear spins of 
14
N (I = ˝) and 15N (I = 1), it is therefore possible to monitor the 
source of NO (Xia et al., 1997). A time-dependent formation of a doublet signal, 
characteristic of 
15
NO–Fe–MGD spectrum was observed (Figure 5A) after incubation of 
L-[
14
N]-arginine-depleted BAEC with L-[
15
N]-arginine for 24 h. Incubation of cells in the 
presence of DMPO and L-[
15
N]-arginine for 24 h gave a similar doublet spectrum 
demonstrating that most of the detected NO were generated from the 
15
N-labeled arginine 
(Figure 5B). This result suggests that the NO generated in BAEC upon DMPO-treatment 
did not originate from the nitrone itself, but rather from the metabolism of L-arginine to 
L-citrulline, and thus, implicates NOS as the source of the NO. 
 
Induction of eNOS- and Akt-phosphorylation in BAEC by DMPO in the absence of 
SIN-1 treatment 
Western blot was performed to detect p-eNOS S1179 in BAEC treated with 
DMPO for 12 h and 24 h. A time-dependent increase in p-eNOS levels was observed due 
to DMPO treatment with a significant 2.2-fold increase after 12 h of incubation. The p-
eNOS level was found to be slightly increased after 24 h of treatment (Figures 6A and 
6B). Since protein kinase B or Akt is known to be an upstream regulator of eNOS and 
results in the phosphorylation of the enzyme (Fulton et al., 1999), p-Akt (Ser-473) levels 
were also measured in the presence of DMPO. DMPO treatment of cells resulted in a 
similar time-dependent increase in p-Akt levels. Incubation of cells with DMPO for 12 h 
and 24 h resulted in 2.7- and 3.5 fold increases in p-Akt levels, respectively (Figures 6A 
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and 6C). Therefore, these observations show that DMPO can increase NO-bioavailability 
in BAEC via phosphorylation of Akt and eNOS.  
 
Inhibition of SIN-1-mediated down-regulation of p-eNOS and p-Akt in BAEC by 
DMPO 
 The phosphorylation levels of eNOS increased by 22% after 2 h of SIN-1 
treatment (corresponding to 0 h of post-incubation with DMPO) but there was a time-
dependent decrease in p-eNOS levels during further incubation of SIN-1 treated cells in 
plain media. After 24 h of post-incubation, the p-eNOS band intensity decreased by 55 % 
compared to control cells (Figures 7A and 7B). However, when SIN-1-challenged cells 
were post-treated with DMPO for 24 h, p-eNOS levels were significantly restored 
(Figures 7C and 7D). In addition, we also observed significant restoration of p-Akt levels 
in SIN-1-treated BAEC upon post-treatment with DMPO (Figures 7C and 7E). These 
observations show that DMPO can increase NO-bioavailability in SIN-1-challenged 
BAEC via phosphorylation of Akt and eNOS.  
 
SIN-1 mediated eNOS dysfunction is independent of BH4 depletion 
 Treatment of BAEC with SIN-1 for 2 h in the absence of DMPO resulted in the 
depletion of BH4-levels but upon incubation in plain media for additional 24 h, BH4-
levels were restored in SIN-1 challenged cells (Figure S6). This indicates that BH4 is 
metabolically replenished after 24 h of incubation, and therefore, is independent of 
DMPO action. We also investigated the effect of DMPO on BH4 state within an hour of 
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SIN-1 administration to the cell but showed no significant change in the BH4 levels 
similar to in the absence of DMPO.   
 
Dual roles of eNOS as target for both SIN-1 and DMPO  
 HEK293 cells were transfected with the cDNAs encoding both wild type and 
mutant (S1179A) bovine eNOS. This mutant eNOS was reported to be resistant to 
phosphorylation and also did not exhibit any Akt-dependent increase in NO-generation 
(Fulton et al., 1999). Western blot results show equal transfection efficiency for both wild 
type and mutant eNOS (Figure S7B) but no NO generation from mutant eNOS and with 
NO generation in wild-type eNOS-transfected cells were observed (Figure S7A). When 
HEK293 cells were transfected with wild type and mutant eNOS plasmids and were 
treated with SIN-1 for 2 h, formation of O2
•−
 was observed using DHE-staining of the 
cells transfected with wild type eNOS-plasmid, whereas in mutant eNOS transfected 
cells, O2
•− 
generation is much lower (Figure 8A-8C). EPR spin trapping to detect ROS 
generation in mutant eNOS-transfected cells gave low levels of ROS even with SIN-1 or 
DMPO treatment (Figure 8D) confirming the role of eNOS S1179 in radical generation. 
It has been shown that phosphorylation of eNOS S1177 at low Ca
2+
 concentrations is 
critical for O2
•− 
generation (Chen et al., 2008). 
 To investigate whether DMPO can attenuate SIN-1 mediated ROS generation in 
HEK293 cells transfected with wild type or mutant eNOS-plasmid, confocal microscopy 
using DCF-DA stain was employed to detect ROS generation and revealed that SIN-
treatment gave a ~4.4-fold increase in DCF-fluorescence intensity and is significantly 
reduced on post-treatment with DMPO (Figure S8A-8B).  
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Discussion 
 Oxidative insult to eNOS can reverse its function from being an NO generator to a 
pro-oxidative enzyme, thereby exacerbating the degenerative processes that have been 
associated with endothelial dysfunction (Cai et al., 2000). In this work, we demonstrated 
how DMPO can reverse eNOS function from being pro-oxidative to that of its normal 
NO synthase function by exploiting the nitrone’s ability to regulate the nitroso-redox 
balance in the cell by scavenging ROS, increasing NO bioavailability, and ultimately 
eNOS phosphorylation.  
 Post-treatment by DMPO of SIN-1-challenged BAEC conferred cytoprotection 
and restored NO production, while post-incubation of BAEC with SIN-1 for an additional 
24 h in plain medium (in the absence of DMPO) gradually increased the oxidative burden 
on the cells. Production of ONOO
─
 via formation of ROS and NO had been implicated in 
SIN-1 cytotoxicity to endothelial cells (Ishii et al., 1999). Although nitrones are known to 
react with ONOO
─
,
 
where ONOO
─
/ONOOH 
 
mediates the formation of the spin adducts 
using DMPO as spin trap (Gatti et al., 1998; Nash et al., 2012), the possibility that 
DMPO may be converting SIN-1 as an NO donor rather than a ONOO
– 
via O2
•− 
scavenging is unlikely since two hours of SIN-1 incubation with cells would not allow 
ONOO
– 
to persist due to its short half-life (1.9 sec at pH 7.4) (Beckman et al., 1990) 
especially in the presence of biological milieu. Furthermore, fluorescence studies showed 
that the half-time for the steady state ONOO
– 
production from SIN-1 range from 14 min 
to 26 min (Martin-Romero et al., 2004). One could envision that after 2 hour incubation 
of cells with SIN-1, ONOO
– 
is released into the cell and could have had reacted already 
causing oxidative damage perhaps to eNOS. Therefore, the observed ROS adducts 
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formation during spin trapping is not a direct reaction of ONOO
– 
with DMPO. These 
results clearly suggest that post-treatment of cells with DMPO attenuates ROS production 
in SIN-1-treated endothelial cells via eNOS dysfunction. 
 ROS-derived ONOO
─
 limits bioavailability of the eNOS cofactor, BH4, resulting 
from either BH4-depletion or oxidation thereby resulting to eNOS dysfunction (Kuzkaya 
et al., 2003). Previous studies also showed that in BAEC, co-incubation of BH4 or 
ascorbic acid with SIN-1 can reverse the effect of SIN-1 on NO production perhaps via 
replenishment of oxidized BH4 or reversal in the oxidation state of the redox-modified 
BH4 (Kuzkaya et al., 2003; Vasquez-Vivar et al., 2002; Xia et al., 1998). However, 
unlike ascorbic acid (Kuzkaya et al., 2003), DMPO does not reverse eNOS function 
through restoration of BH4 levels during initial and 24 hours of SIN-1 treatments, and 
that the observed reduced NO and increase ROS productions could be a result of other 
mechanisms other than uncoupling due to BH4 oxidation. 
 Therefore, the role of eNOS activation via phosphorylation was investigated to 
explain the observed increase in NO production in DMPO-treated cells. Phosphorylation 
of eNOS S1179 is known to activate eNOS by stimulating the flux of electrons within the 
reductase domain (Harris et al., 2001; McCabe et al., 2000; Michell et al., 2001).  Under 
oxidative stress conditions, eNOS generates O2
•−
 and phosphorylation of eNOS S1179 is 
inhibited leading to decrease in NO production. How phosphorylation of eNOS S1179 is 
regulated to maintain the O2
•−
-NO balance under oxidative stress conditions is not 
completely understood (Xia et al., 1996) but it has been proposed that eNOS 
phosphorylation is redox-sensitive and is activated by  PI3K/Akt pathway (Dimmeler et 
al., 1999; Fulton et al., 1999) and by other kinases (Alhosin et al., 2013). Regulation of  
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ATP levels and activation of other kinases such as p38 MAPK and JNK by DMPO, 
therefore, warrants further investigation. This study, nevertheless, demonstrates that 
DMPO can reverse eNOS dysfunction through decreased ROS production, increased in 
NO bioavailability and increased phosphorylation of eNOS S1179  Akt activation. 
 Traditional antioxidants such as ascobic acid and N-acetyl cysteine have been 
explored for their ability to prevent or reverse eNOS uncoupling in BAEC (Kuzkaya et 
al., 2003) and in diabetic rat hearts (Okazaki et al., 2011) through an increase in the 
BH4/BH2 ratio. Recently, lipophilic NO-donor and lipophilic antioxidants, when 
introduced as a hybrid molecule and not as a mixture, can exhibit cardiac protection from 
I/R  through significant reduction of infarct size with improved recovery of cardiac 
function (Rastaldo et al., 2012), however, the mechanism of this protection was not clear. 
Moreover, magnesium lithospermate B have been shown to protect endothelium from 
hyperglycemia-induced dysfunction via eNOS phosphorylation, and induction of phase II 
enzymes by Nrf-2 nuclear translocation, while α-lipoic acid was claimed to be not able to 
cause these effects (Traynham et al., 2012).  
 Cardiometabolic disease is a growing health problem that is a combination of 
various risk factors such as hypertension, hyperglycemia and elevated plasma triglyceride 
levels, leading to the development of Type 2 diabetes and cardiovascular diseases. While 
the antioxidants mentioned above could be promising, their therapeutic application could 
be limited in the treatment of cardiometabolic diseases since unlike nitrones, their modes 
of action may only be limited to few mechanisms (Zamora et al., 2013). Findings 
presented in this present work and in our past studies (Das et al., 2012; Durand et al., 
2009; Traynham et al., 2012; Zuo et al., 2009) showed that nitrones offer opportunities 
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for the application of nitrones in the treatment of cardiometabolic disorders such as 
hypertension  and hyperglycemia which are associated with endothelial dysfunction and 
depletion of cellular antioxidant pool since nitrones do not only scavenge ROS (Durand 
et al., 2008; Durand et al., 2009) but also acts through NO donation (Locigno et al., 
2005); salvaging METC activity (Zuo et al., 2009); increase METC biogenesis (Zuo et 
al., 2009); inhibition of mitochondrial polarization leading to down regulation of pro-
apoptotic signaling pathways; induction of phase II enzyme activities via NRF-2 nuclear 
translocation (Das et al., 2012); increased myocyte contraction via increased 
sarcoplasmic reticulum Ca
2+
 handling (Traynham et al., 2012) and in this study, reversal 
of eNOS dysfunction.  
 Future work needs to investigate how DMPO activates Akt by immuno-spin 
trapping of the relevant proteins and role of nitrones as a potential phosphatase inhibitor, 
since protein phosphatase 2A (PP2A) was also reported to decrease eNOS 
S1179 phosphorylation. Therefore, therapeutic agents that can target cytosolic matrix and 
affect kinase mediated phosphorylation processes in the cell may be able to up-regulate 
eNOS. Attempts had been made to conjugate cyclic nitrones to several target specific 
groups in order to facilitate their delivery to specific subcellular compartments (Durand et 
al., 2010; Durand et al., 2003; Durand et al., 2009) since the poor target specificity of 
some of the natural antioxidants such as vitamin E, vitamin C, or lipoic acid are limiting 
their applications against ROS-induced CVDs (Kizhakekuttu et al., 2010; Shay et al., 
2009; Willcox et al., 2008). Considering that eNOS is mostly localized near the cell 
membrane and that mitochondria and sarcoplasmic reticulum are mostly cytosolic, the 
use of nitrones that can specifically target these compartments can provide opportunities 
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to identifying which targeted cellular event/s contributes the greatest to I/R injury and 
which target-specific nitrone will exhibit the most robust protection can give valuable 
insights into the mechanisms of nitrone protection. To date, targeting oxidative stress at 
the site/s of their origination still remains an attractive strategy for cardiovascular 
prevention and therapy (Munzel et al., 2010). Therefore, deeper understanding of radical 
sources and mechanisms of oxidative stress, and the development of more target specific 
antioxidants with multi-functional action such as those exhibited by nitrones are 
necessary.  
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Figure Captions 
 
Figure 1. Effect of DMPO on SIN-1 induced cytotoxicity. (A) Dose-dependence. (B) 
Time-dependence. Measured using MTT assay. All data are represented as the mean ± 
SEM, *p < 0.05 vs. control (untreated cells), **p < 0.05 vs. SIN-1 treated cells, where n 
= 6. 
 
Figure 2. Effect of DMPO on SIN-1 induced ROS generation in BAEC. (A) Confocal 
micrographs of ROS generation in BAEC treated with SIN-1 (500 µM) alone and those 
post-incubated with DMPO (100 µM). (B) Plot of average DCF- fluorescence obtained 
from 100 cells.  All data are represented as mean ± SEM, *p < 0.05 vs. control (untreated 
cells), **p < 0.05 vs. SIN-1 treated cells, where n = 3.  (C) Representative X-band EPR 
spectra and simulated (dotted lines) of radical adducts formed in SIN-1 treated BAEC, 
with and without DMPO (100 µM) incubation using EMPO/Me-β–CD as spin trap (see 
Table S2 for complete simulated EPR parameters). (D) Plot of the concentrations of the 
HO2
•
, HO
•
 and C-centered adducts from Figure 2C.  
 
Figure 3. Restoration of NO production and eNOS activity in SIN-1 treated BAEC 
by DMPO. (A) X-band EPR spectra of NO using Fe(MGD)2 spin trap generated form 
SIN-1 treated BAEC and with or without post-incubation with DMPO (100 µM). (B) Plot 
of the relative low field EPR peak intensity of Fe(MGD)2-NO. (C) eNOS activity as 
measured by arginine to citrulline assay from BAEC treated with SIN-1 with and without 
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DMPO incubation. All data are represented as mean ± SEM, *p < 0.05 vs. control 
(untreated cells), **p < 0.05 vs. SIN-1 treated cells, where n = 3. 
 
Figure 4. Time-dependent increase in NO production in DMPO-treated BAEC. (A) 
X-band EPR spectra of NO using Fe(MGD)2 spin trap generated in BAEC during 0 to 24 
h of incubation with DMPO (100 μM) and NOS inhibitor, L-NAME. (B) Plot of the 
relative low field EPR peak intensity of Fe(MGD)2-NO. Results are represented as mean 
± SEM, *p < 0.05 vs. control (untreated cells), where n = 3. 
Figure 5. Determination of the source of NO. (A) X-band EPR spectra of 
15
NO–Fe–
MGD showing the characteristic doublet peak produced from BAEC supplemented with 
L-[
15
N] arginine at various incubation times. (B)  EPR spectra of NO adducts formed 
from BAEC incubated alone in medium containing L-[
14
N] arginine;  L-[
15
N] arginine 
containing medium; and L-[
15
N] arginine containing medium supplemented with DMPO. 
All experiments were performed at least n = 3. 
 
Figure 6. Effect of DMPO on the phosphorylation status of eNOS and AKT proteins 
in BAEC. (A) Western blot expression levels of p-eNOS, total eNOS, p-Akt, and t-Akt in 
BAEC treated with 100 μM DMPO at 12 h and 24 h incubation. Densitometric analysis 
of the expression levels of (B) p-eNOS (B) and (C) p-Akt. All data are represented as 
mean ± SEM, *p < 0.05 vs. control (untreated cells), where n = 3. 
 
Figure 7. Modulation of eNOS and Akt phosphorylation by DMPO in SIN-1 treated 
cells. (A) Western blot analysis; and (B) densitometric analysis of p-eNOS S1179 and t-
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eNOS expression levels in BAEC treated with SIN-1 (500 μM, 2 h)  and post incubated 
in plain media (without SIN-1) at various incubation times. Results are represented as 
mean ± SEM,*p < 0.05 vs. control (untreated cells). (C) Western blot analysis of p-eNOS 
S1179, t-eNOS, p-Akt (ser 473) and t-Akt expression in BAEC treated with SIN-1 (500 
μM) alone and post-incubated with DMPO (100 μM). Densitometric analysis of the 
expression levels of (D) p-eNOS S1179 and (E) p-Akt from the above mentioned 
conditions. Results are represented as mean ± SEM, *p < 0.05 vs. control (untreated 
cells), **p < 0.05 vs. SIN-1 treated cells, where n = 3. 
 
Figure 8. Detection of ROS generation in wild type and mutant eNOS cDNA-
transfected HEK293 cells in the presence of SIN-1. Confocal DHE and DAPI images 
of untreated and SIN-1 treated HEK293 cells transfected with cDNAs encoding (A) wild 
type eNOS S1179; (B) mutant eNOS cDNA S1179A. (C) Plot of relative average DHE-
fluorescence intensities (n = 100 cells). Data are represented as mean ± SEM, *p < 0.05 
vs. control (non-transfected cells) and **p < 0.05 vs. SIN-1 treated wild type eNOS 
S1179 transfected cells. (D) X-band EPR detection of radical generation using 
EMPO/Me-β–CD from mutant eNOS cDNA transfected HEK293 cells that are untreated 
(top) and treated with SIN-1 (middle), and post-incubated with DMPO (bottom). All 
experiments were performed in triplicates. 
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